Join the premier forum for Hatch-Waxman litigators and pharmaceutical patent practitioners.
Widely recognized as the industry gold standard, this event unites leaders from brand-name and generic drug companies, alongside federal judges, the U.S. PTOâs PTAB, the FTC, and the FDA, to tackle the critical legal, regulatory, and business issues shaping pharmaceutical patent litigation. Focusing on pre-suit strategies, case filings, final adjudications, and everything in between, this conference provides unparalleled insights and actionable takeaways for navigating the complex and high-stakes world of Paragraph IV disputes. Join us to stay at the forefront of legal developments and connect with top professionals in this dynamic and evolving field.
Gain Insights on Evolving Policies, Industry Trends, and Litigation Strategies
- Prepare for a New Administration
Timely analysis and insights on the new administration’s policy priorities and the projected impact on small molecule IP.
- Brand and Generic Focused Think Tanks
TExplore the brand and generic point of view on how the small molecule manufacturers are evolving, emerging business concerns and litigation trends.
- View from the Bench
Our distinguished panel of District Court Judges will provide a closer look at the Paragraph IV litigation dockets.
Key Conference Highlights
Status of the Inflation Reduction Act and Future Drug Price Negotiations
AI’s Impact on Drug Discovery and Patent Law
Focus on Litigation and Agency Decisions Following the Demise of the Chevron Doctrine in Loper V. Raimondo
Exploring the On-Sale Bar and Applicability of Prior Art
Orange Book Delisting Attempts
Navigating ODP and Patent Family Dynamics
3,700+
Attendees
560+
Speakers
110+
Sponsors
Key Conference Takeaways
Hear from FDA, FTC and other key government agencies about regulatory and enforcement priorities
Meet over a dozen leading senior in-house patent counsel from brands and generics
Learn from a Chambers-ranked âwhoâs whoâ of the Hatch-Waxman bar from New York, DC, and Chicago
Who You Will Meet
Patent attorneys and litigators (in-house & law firms) who represent:
- Brand name pharmaceutical companies
- Generic pharmaceutical companies
- Biopharmaceutical companies
Earn CLE/Ethics Credits
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.
Learn moreSponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein, Senior Business Development Manager
Phone: 201-282-7274
Email: [email protected]
